A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
The study is being conducted to evaluate the efficacy and safety of SHR-1210 in combination with Famitinib plus chemotherapy in subjects with NSCLC.
Non-squamous Non-small-cell Lung Cancer
DRUG: Camrelizumab;Pemetrexed and Carboplatin; Famitinib;|DRUG: Camrelizumab;Pemetrexed and Carboplatin;Placebo
Part 1：Serum concentrations of Camrelizumab, Cycle 2; each cycle is 21 days (up to 42 days)|Part 1：Plasma concentrations of Famitinib, Cycle 2; each cycle is 21 days (up to 42 days)|Part 1：Area Under the Plasma Concentration Versus Time Curve (AUC) of Famitinib., Cycle 2; each cycle is 21 days (up to 42 days)|Part 1：Maximum Concentration (Cmax) of Famitinib., Cycle 2; each cycle is 21 days (up to 42 days)|Part 1：Time to Maximum Concentration (Tmax) of Famitinib., Cycle 2; each cycle is 21 days (up to 42 days)|Part 1：Half-life (t1/2 z) of Famitinib., Cycle 2; each cycle is 21 days (up to 42 days)|Part 1：Apparent Clearance (CL/F) of Famitinib, Cycle 2; each cycle is 21 days (up to 42 days）|Part 1：Vz/F of Famitinib., Cycle 2; each cycle is 21 days (up to 42 days)|Part 2: Progression-free Survival (PFS) as Assessed by BICR according to RECIST 1.1., up to 24 months
Part 1:Objective Response Rate (ORR) as Assessed by investigators, Cycle 2; each cycle is 21 days (up to 42 days)|Part 1:Duration of Response (DOR) as Assessed by investigators, Cycle 2; each cycle is 21 days (up to 42 days)|Part 1:Progression-free Survival (PFS) as Assessed by investigators, Cycle 2; each cycle is 21 days (up to 42 days)|Part 1:Overall Survival (OS)., Up to approximately 60 months|Part 2:Overall Survival (OS), Up to approximately 60 months|Part 2:Progression-free Survival (PFS) as Assessed by investigators according to RECIST 1.1., up to 24 months|Part 2:Objective Response Rate (ORR) as Assessed by investigators and BICR according to RECIST 1.1, up to 24 months|Part 2:Duration of Response (DOR) as Assessed by investigators and BICR according to RECIST 1.1, up to 24 months|Part 2:Disease Control Rate(DCR) as Assessed by investigators and BICR according to RECIST 1.1, up to 24 months|Part 2:Number of Participants With Adverse Events and Serious Adverse Event as Assessed by CTCAE v5.0., up to 24 months
The study is being conducted to evaluate the efficacy and safety of Camrelizumab in combination with Famitinib plus chemotherapy in subjects with NSCLC.